Abstracts

796 – Changes in Doravirine Pharmacokinetics During Pregnancy: A Longitudinal Single-Dose Study

Background Physiologic changes that occur during pregnancy can significantly alter the pharmacokinetics (PK) of antiretrovirals (ARV), potentially impacting maternal HIV suppression and vertical transmission risk.  Doravirine (DOR), a once-daily potent NNRTI with a strong safety profile, could be used during pregnancy if data were available to optimize dosing strategies during gestation and post-partum.     Methods…

788 – Delamanid and Linezolid PK in the Treatment of Drug-Resistant Pulmonary TB: Results From ACTG 5356

Background Optimal linezolid (LZD) dosing for treatment of drug-resistant pulmonary tuberculosis (DR-TB) is not established. A5356 was a phase 2, randomized clinical trial comparing two LZD dosing strategies plus delamanid (DLM), bedaquiline, and clofazimine for DR-TB. Additional objectives were to describe DLM and LZD PK and their relationship to outcomes. Methods Participants (pts) were randomized…

861 – Outcomes of Children and Adolescents With Viraemia While on Dolutegravir

Background Pediatric dolutegravir (DTG) formulations were introduced in many sub-Saharan African countries in 2019. However, little is known about the outcomes of DTG failure in children and adolescents living with HIV.  Methods The Ndovu Study is a multi-country prospective cohort in Kenya, Mozambique, Lesotho and Tanzania enrolling people living with HIV on DTG for at least 6 months…

278 – Perturbations in the Myeloid Cell Compartment Persist in Early-Treated People Living With HIV

Background Despite antiretroviral therapy (ART) initiation during acute HIV infection (AHI), persistent immune alterations remain. To better understand the deviation from immune homeostasis, we performed longitudinal phenotypic and transcriptional profiling of peripheral blood mononuclear cells (PBMCs) from early-treated people living with HIV (PLWH) using HIV uninfected controls as reference population. Methods Matched PBMC samples were…

560 – Prevalence of InSTI Drug Resistance: Population-Based Data From 4 African Countries, 2019-2022

Background With excellent tolerability, effectiveness and high barrier to drug resistance, integrase strand transfer inhibitors (INSTI) are widely used in HIV treatment. We examined population-based INSTI DR mutation (DRM) prevalence in four high HIV burden African countries using INSTI as first-line antiretroviral (ARV) therapy. Methods We pooled and analyzed data from Population-based HIV Impact Assessments…

833 – Sex Matters: A Bayesian Approach to Analyzing Sex Differences in an African Pediatric Cohort

Background Females often present with lower plasma viral loads and higher CD4 counts early in infection yet may experience greater HIV-related morbidity and mortality. In contrast, evidence among infants living with HIV (ILHIV) remains limited and sometimes conflicting, particularly regarding viral dynamics, immune reconstitution, and reservoir size. This gap hampers understanding of sex-related differences in…

860 – Global Cohort Analysis of Dolutegravir Viral Response in Children and Adolescents Living With HIV

Background We describe virological outcomes in a large multiregional cohort of children and adolescents living with HIV (CALHIV), aged 0-19 years, receiving dolutegravir (DTG)-based ART in low- and middle-income countries.  Methods We included all CALHIV initiating or transitioning to DTG-based ART since 2018, to 2024 in clinics across West, East, Central and Southern Africa, the…

1073 – California Legislation Allowing Pharmacist Dispensation of PrEP Increased Pharmacist Prescribing

Background California (CA) State Bill 159 (SB159), enacted in October 2019, aimed to expand PrEP access and reduce HIV incidence by broadening authority for pharmacists to prescribe PrEP without physician approval and prohibiting insurance preauthorization requirements.  This study examined SB159’s impact on pharmacist PrEP prescribing, changes in number of PrEP prescriptions filled, and the relation between…